This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

MannKind Inhaled Insulin Matches Injections -Study

Posted: Thursday, September 21, 2006

An inhaled insulin being developed by MannKind Corp produces comparable improvements in blood sugar control to rapid-acting insulin analog (RAA) given by injection, researchers said on Saturday.

The positive Phase III clinical trial results were presented at the annual meeting of the European Association for the Study of Diabetes.

MannKind Chief Scientific Officer Peter Richardson added that no adverse effect on pulmonary function was observed with the Californian company's Technosphere Insulin system, reassuring investigators that it does not harm the lungs.

Encouragingly, given the link between diabetes and obesity, Technosphere Insulin patients lost weight during the treatment period, unlike those given injections.

The 24-week study included 308 patients with Type 2 diabetes.

MannKind is one of several companies racing to develop inhaled forms of insulin, which are more convenient than the normal practice of injections.

The market leader is Pfizer Inc, whose Exubera product, which uses an inhaler developed by Nektar Therapeutics, has already been launched in major markets.

Presented at the annual meeting of the European Association for the Study of Diabetes. (EASD)

Source: Diabetes In Control